Get the Stockscreener App
0.00
100.00%
-0.5266
Oncternal Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
See More
Previous Close:
$0.5266
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$1.56M
Revenue:
-
Net Income/Loss:
$-34.58M
P/E Ratio:
0.00
EPS:
-11.69
Net Cash Flow:
$-26.63M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$9.88
Oncternal Therapeutics Inc Stock (ONCT) Company Profile
Name
Oncternal Therapeutics Inc
Sector
Industry
Phone
(858) 434-1113
Address
12230 EL CAMINO REAL, SAN DIEGO, CA
Compare ONCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCT
Oncternal Therapeutics Inc
|
0.00 | 1.56M | 0 | -34.58M | -26.63M | -11.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Oncternal Therapeutics Inc Stock (ONCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-21 | Initiated | Oppenheimer | Outperform |
| Feb-23-21 | Initiated | Northland Capital | Outperform |
Oncternal Therapeutics Inc Stock (ONCT) Latest News
Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.com - Defense World
Future Industry Growth Of Metastatic Prostate Cancer Market - openPR
Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC - GlobeNewswire
From Nasdaq to Dark: What's Next for Oncternal After March 2025 Delisting? - StockTitan
B-Cell Non-Hodgkin Lymphoma Pipeline 2024: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Biegene, Oncternal Therapeutics, ZAI Lab, Pfizer, Xynomic Pharma, SystImmune Inc., Autolus - Barchart
Ewing Sarcoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
3 Top Tech Stocks to Buy Right Now - The Globe and Mail
Oncternal Therapeutics (ONCT) Expected to Announce Quarterly Earnings on Thursday - Defense World
Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, - openPR
Billionaire Investor David Tepper Doubles Down on These Stocks. Should You Follow? - The Globe and Mail
Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com - Defense World
Metastatic Prostate Cancer Clinical and Non-Clinical Studies, - openPR
Head-To-Head Survey: Oncternal Therapeutics (NASDAQ:ONCT) & Organigram (NASDAQ:OGI) - Defense World
Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com - Defense World
Future-Proofing Growth of Metastatic Prostate Cancer Market, - openPR
IBM Stock 2025 Outlook: Can AI and Cloud Revive IBM’s Growth? - The Globe and Mail
StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - Defense World
B-cell Lymphoma Pipeline Update 2024: FDA Approvals, - openPR
Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com - Defense World
Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference - Marketscreener.com
CELUCelularity Inc. Latest Stock News & Market Updates - StockTitan
ONCT stock touches 52-week low at $0.61 amid market challenges - Investing.com Australia
ONCT stock touches 52-week low at $0.61 amid market challenges By Investing.com - Investing.com South Africa
StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - Defense World
ONCT stock touches 52-week low at $0.83 amid market challenges By Investing.com - Investing.com South Africa
ONCT stock touches 52-week low at $0.83 amid market challenges - Investing.com
Oncternal shares to be delisted from Nasdaq - Investing.com
Oncternal Therapeutics Reports Q3 2024 Earnings - TipRanks
ONCT (Oncternal Therapeutics) 9-Day RSI : 33.20 (As of Nov. 20, 2024) - GuruFocus.com
Oncternal announces workforce reduction, executive changes - Investing.com
Oncternal Therapeutics to Cut Most of Its Workforce - MarketWatch
Oncternal Therapeutics Announces Workforce Reduction and Executive Changes - TipRanks
ONCT Stock Touches 52-Week Low at $1.03 Amid Market Challenges - Investing.com
Phase 1/2 trial of ONCT-534 in mCRPC has been terminated - Urology Times
Oncternal Therapeutics, Inc. Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - Marketscreener.com
Nikola (NKLA) Q3 Earnings: What To Expect - The Globe and Mail
Oncternal reports positive prostate cancer treatment results By Investing.com - Investing.com Australia
Oncternal reports positive prostate cancer treatment results - Investing.com India
Oncternal Therapeutics Announces Updated Safety and - GlobeNewswire
B-Cell Non-Hodgkin Lymphoma Pipeline Assessment 2024: Therapies, Clinical Trials, and Growth Prospects | Biegene, Oncternal Therapeutics, ZAI Lab, Pfizer, Xynomic Pharma, SystImmune Inc., Autolus - Barchart
Oncternal Therapeutics Inc Stock (ONCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
2.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):